Fortis Healthcare Limited has announced the approval of its unaudited standalone and consolidated financial results for the quarter and six months ended September 30, 2025. Key highlights include a consolidated total income of ₹235.40 crore for the quarter and a net profit of ₹32.88 crore. The board has taken steps to recover dues from erstwhile promoters, but investigations are still ongoing.
Financial Performance
The Board of Directors has approved the unaudited standalone and consolidated financial results for Q2 2025-26. Here are some of the key financial figures:
- Consolidated Total Income: ₹235.40 crore
- Consolidated Net Profit: ₹32.88 crore
Segmental Performance
A breakdown of the total value of sales and services (revenue from operations) across segments reveals:
- Healthcare: ₹197.38 crore
- Diagnostics: ₹39.96 crore
Ongoing Investigations and Matters
The company continues to address ongoing investigations involving erstwhile promoters, and is cooperating with regulatory bodies. Fortis is undertaking measures for recovery and compliance.
Additional Information
The earnings per equity share for continuing operations (not annualised) are:
- Basic earnings per share: ₹4.26
- Diluted earnings per share: ₹4.26
The company entered into an operation and maintenance service agreement with Gleneagles Healthcare India Private Limited effective July 23, 2025, and a sub-lease agreement with R.R Lifesciences Pvt. Ltd effective September 1, 2025.
Auditor’s Report
The limited review report filed by the auditors remains unmodified.
Security Coverage
The security cover ratio for the non-convertible debentures is 1.24 on book value and 1.49 on market value. The company continues to adhere to all financial and non-financial covenants as stipulated in their Debenture Trust Deed.
Source: BSE
